耐火性腹腔动脉动脉和结构性心脏病患者的修饰性交友切除术:单中心体验
Filippo Maria Cauti1,2, Pietro Rossi3, Stefano Bianchi3
1Arrhythmology Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. filippocauti@hotmail.it.
概括
修改心交感性缩与星状节省是一种安全有效的治疗耐火性心室性心力衰竭. 这种新的神经调节技术可以减少植入式心脏转换器-除器的冲击,并改善结构性心脏病患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 心脏外科手术 心脏外科手术
- 神经调节是一种神经调节.
背景情况:
- 在结构性心脏病 (SHD) 中,耐火性心室动脉冲动 (VT) 带来了重大管理挑战.
- 心脏交感性缩 (CSD) 是一种新兴的神经调节技术.
- 一种修改后的CSD方法与星状质 (SG) 节省提供了一个新的治疗策略.
研究的目的:
- 为了评估修改后的CSD与SG节省的中长期临床结果.
- 评估该技术在SHD和耐火静脉瘤患者中的安全性和有效性.
主要方法:
- 一系列连续的SHD和耐火性静脉瘤患者接受修改的CSD被纳入.
- 收集了临床特征和周围手术数据.
- 主要结局是持续静脉动的复发;次要结局包括植入式心脏转换器-除器 (ICD) 冲击.
主要成果:
- 15名患者 (100%男性,平均年龄69.2岁,LVEF 37%) 患有耐火性静脉瘤,接受了修改的心脏病.
- 没有发生重大周围手术并发症.
- 在15个月的中位随访后,在47.6%的患者中观察到静脉瘤复发,但所有患者都显示ICD冲击的显著减少 (每个患者3.1到0.3,p=0.001).
- 双边CSD和VT周期长度<340毫秒与更好的结果有关.
结论:
- 修改后的CSD与SG节省是一种安全,快速和有效的治疗耐火性静脉瘤患者的SHD.
- 这种技术为管理复杂心律不整提供了一个有前途的选择.
- 进一步的研究是有必要的,以优化患者选择和程序技术.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
21
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
21
Heart Failure Drugs: β-Blockers
342
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
342
Disturbances in Heart Rhythm
972
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
972
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
747
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
747
Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594


